About Heptares | Board

Fiona Marshall, Founder, Director, and Chief Scientific Officer

Fiona has a BSc in biochemistry from Bath University and a PhD in neuroscience from Cambridge University. She has more than 25 years' experience in drug discovery with particular expertise on GPCRs. She led the first group to show that GPCRs could form heterodimers and has published more than 80 peer-reviewed papers in the area of GPCRs. She spent 12 years at GlaxoWellcome/GlaxoSmithKline where she held a number of senior positions including Head of the Department of Molecular Pharmacology. She was Director of Discovery Pharmacology, Europe for Millennium Pharmaceuticals and then spent several years as an independent consultant to a variety of venture capital and biotech companies, including Inpharmatica, Merlion, Galapagos, Paradigm, Cancer Research Technology, Shire, CellAura, Bioimage, Chroma, Ablynx and Sentinel. Fiona is currently the chair of the MRC DPFS committee and is on the Translation Advisory Group of the Francis Crick Institute and on the Scientific Advisory board of Open Targets. She is also on the Board of Trustees of Alzheimer’s Research UK (ARUK) and on the ARUK Drug Discovery Alliance Advisory Group. Fiona won the 2012 WISE Women of Outstanding Achievement for Innovation and Entrepreneurship and received the Malcolm Campbell Memorial Prize 2015, awarded by the UK Royal Society of Chemistry’s Biological and Medicinal Chemistry Sector, in recognition of her contribution to GPCR drug discovery. She was elected a Fellow of The Academy of Medical Sciences in 2016.

Fiona is Executive VP and CSO of Sosei Group Corporation.

Malcolm Weir, Founder, Chairman and Chief Executive
Officer

Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company. Inpharmatica was sold to Galapagos NV in 2006. He joined MRC Technology in 2006 in order to establish Heptares Therapeutics Ltd in July 2007, as co-founder and CEO. Malcolm was elected Visiting Professor of Biochemistry at Imperial College, London in 1997 and is on the Chemical Biology Advisory Board at the same university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004-2011. Malcolm received the Malcolm Campbell Memorial Prize 2015, awarded by the UK Royal Society of Chemistry’s Biological and Medicinal Chemistry Sector, in recognition of his contribution to GPCR drug discovery. In 2016, he received an honorary DSc from the University of Hertfordshire for services to research.

Malcolm is Executive VP and Chief R&D Officer of Sosei Group Corporation.

© 2012-2017 Heptares Therapeutics